Discovery of TAK-659 an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)

Leave this area blank for abstract info.

Betty Lam*, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky, and Zhe Nie

Discovery of TAK-659 an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)

Betty Lam ^{a,*}, Yasuyoshi Arikawa ^b, Joshua Cramlett ^c, Qing Dong ^d, Ron de Jong ^a, Victoria Feher ^e, Charles E. Grimshaw ^a, Pamela J. Farrell ^a, Isaac D. Hoffman ^a, Andy Jennings ^a, Benjamin Jones ^a, Jennifer Matuszkiewicz ^f, Joanne Miura ^a, Hiroshi Miyake ^b, Srinivasa Reddy Natala ^g, Lihong Shi ⁱ, Masashi Takahashi ^b, Ewan Taylor ^a, Corey Wyrick ^a, Jason Yano ^h, Jonathan Zalevsky ⁱ and Zhe Nie ^f

^aTakeda California, 10410 Science Center Drive, San Diego, CA 92121, USA

^bTakeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan

^cPolyScientific Consulting Inc. 4624 Aragon Dr, San Diego, CA 92115

^dFronThera US Pharmaceuticals, 11526 Sorrento Valley Road, Suite D, San Diego, CA 92121

^eSchrödinger, Inc. 5820 Oberlin Drive, Ste. 203, San Diego, CA 92121

^fCelgene Quanticel Research, 9393 Towne Center Drive, Suite 110, San Diego, California 92121, USA

^gNeuropore Therapies, 10835 Road to Cure, Suite 230 San Diego, CA 92121

^hBeryllium Discovery, 3 Preston Ct., Bedford, MA 01730

ⁱNektar Therapeutics, 455 Mission Bay Boulevard South San Francisco, CA 94158

ARTICLE INFO

Article history:

Received

Revised

Accepted

Available online

Keywords:

SYK

Kinase inhibitor

Kinase selectivity

Structure-based drug discovery

Leukemia

Lymphoma

ABSTRACT

Spleen tyrosine kinase (SYK) is a non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells. SYK is a key mediator for a variety of inflammatory cells, including B cells, mast cells, macrophages and neutrophils and therefore, an attractive approach for treatment of both inflammatory diseases and oncology indications. Using in house co-crystal structure information, and structure-based drug design, we designed and optimized a novel series of heteroaromatic pyrrolidinone SYK inhibitors resulting in the selection of the development candidate **TAK-659**. **TAK-659** is currently undergoing Phase I clinical trials for advanced solid tumor and lymphoma malignancies, a Phase Ib study in advanced solid tumors in combination with nivolumab, and PhIb/II trials for relapsed/refractory AML. 2016 Elsevier Ltd. All rights reserved.

Spleen Tyrosine Kinase (SYK) is a 72 kD non-receptor cytoplasmic tyrosine kinase that is primarily expressed in hematopoietic cells. SYK is a key mediator for a variety of inflammatory cells and immunology signaling pathways, including B cell receptor (BCR) in B cells, FcγR in lymphoid and myeloid cells, and FcεRI in mast cells, basophils, and neutrophils.^{1a-f} Recent studies have implicated abnormal SYK activation in several hematopoietic malignancies including chronic lymphocytic leukemia (CLL), peripheral T-cell lymphoma (PTCL), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).^{2a-c} Research has also identified an oncogenic collaboration between SYK and FMS-like tyrosine kinase 3 (FLT3) in AML. In addition, activating mutations within the FLT3 gene on chromosome 13q12 have been detected in approximately 30% of AML patients and accounted for one of the most frequently identified genetic alterations in AML.^{3a-b} Internal tandem duplication (ITD) of the FLT3 gene, occurs at high frequency in AML and SYK, is critical for the development of FLT3-ITD-induced myeloid neoplasia since it is more highly activated in primary human FLT3-ITD-positive AML than its FLT3 wild-type (WT) AML counterparts, and moreover transactivates FLT3 by direct phosphorylation.^{4a-c} Hence, SYK inhibition provides a desirable mechanistic intervention for

potential treatment of inflammatory diseases and oncology indications.

In recent years, a number of SYK inhibitors have advanced to clinical trials for inflammatory disease indications, such as asthma, arthritis and allergic diseases.⁵ Most have been terminated in Phase I/II studies due to various reasons. An example is fostamatinib (R-788). Fostamatinib showed promising Phase I results in patients with rheumatoid arthritis, however little efficacy was observed in Phase II studies.^{6a-b} When dosed at 150mg BID, patients were experiencing adverse events, such as diarrhea, upper respiratory tract infections, neutropenia, elevated alanine transaminase (ALT), and hypertension. Fostamatinib is a non-selective SYK inhibitor, thus the observed undesirable side effects were hypothesized to be caused by off-target inhibition.^{7a-b} In the past, generation of selective SYK inhibitors has been challenging,^{5,7c,d} however, as shown in this article, we succeeded in the design of highly selective SYK compounds by utilizing structure-based drug design (SBDD). Herein we report the discovery of **TAK-659**, a potent and selective SYK inhibitor that is currently undergoing Phase Ib/II evaluations in adult patients with solid tumors and hematologic malignancies.

Supported by high-throughput protein crystallization technology and applying SBDD strategy, we had designed a novel series of dihydropyrrolopyrimidinone SYK inhibitors, which led to the discovery of our first lead compound, compound **1**. A co-crystal structure of compound **1** in the SYK active site⁸ was obtained (**Figure 1**). Compound **1** binds to the hinge region of SYK which adopts the active DFG-in (Phe513) conformation. The lactam core makes two direct hydrogen bonds (HBs) with the hinge through Ala451, and Glu449. Multiple interactions are observed between the primary and secondary amines of the cyclohexyl ring with the polar region comprised of Arg498, Asn499, and Asp512. One of the pyrimidine ring nitrogen atoms forms a water mediated HB (HOH136; cyan) with Ser511. Leu377 and Pro455 provide a lipophilic pocket for the *m*-methyl aniline ring of compound **1**.

Figure 1. Co-crystal structure of compound **1** in the SYK active site.

While compound **1** (see **Scheme 1** in supplemental data for synthesis)^{9a} is an efficient and potent inhibitor of SYK (IC₅₀ = 13 nM; LE = 0.41; LipE = 4.3), its cellular potency as measured by inhibition of phosphorylation of BLNK, a direct cellular substrate of SYK,¹⁰ and selectivity toward JAK3 were not optimal. It also had hERG and CYP liabilities (**Figure 2**). Our goals for lead optimization were to improve cellular potency and JAK3 selectivity, reduce inhibitions toward CYPs and hERG, and replace the aniline group, which is a known toxicophore that can potentially form reactive metabolites.

	SYK IC ₅₀	13 nM
	Cell ¹ EC ₅₀	35 nM
	Kinase	Fold-Selectivity
	JAK3	19
	ZAP70	21
	VEGFR2	250
	CYP (2D6)	7.9 μM
	cLogP	3.6
	LE ²	0.41
	LipE ³	4.3
	E _n (HLM) ¹⁰	0.25
	hERG	41% @ 10 μM

¹Cellular BLNK phosphorylation inhibition
²Ligand efficiency (LE): 1.4(-logIC₅₀)/N
³Lipophilic Efficiency (LipE) = LipE = pIC₅₀ - LogP
 Human liver microsomes extraction ratio: E_n(HLM)

Figure 2. Chemical and physical properties of compound **1**.

One way to improve potency and selectivity was to disrupt the water-mediated HB between the pyrimidine nitrogen and Ser511. Since water HOH136 was not a structural water, replacing it should be entropically beneficial to enhance potency. From SAR development (**Table 1**, and **Scheme 2** in supplemental for syntheses of compound **2a-f**),¹⁰ displacement of the water with

different **R** groups increased both enzyme (3 to 26-fold) and cellular potency (7 to >12-fold), while kinase selectivity was compromised. Most of these compounds inhibited CYPs, with the exception of compound **2b**. Although compound **2b** showed improved enzyme and cellular potency, was selective against JAK3 (170-fold selective compared to SYK potency) and had no CYPs liability, further study showed that it inhibited hERG. To mitigate the hERG liability and remove the problematic aniline group, a number of aniline mimetics were synthesized. As shown in **Table 2**, the cyclized pyrazolopyridine compound **3a**, retained both enzyme and cellular potency, possessed improved kinase selectivity, and did not inhibit CYPs. Upon further optimization by lowering molecular weight and cLogP, and improving LipE, compound **3b**, with methylpyrazole, was identified. Compound **3b** had a good in vitro profile, did not have CYP or hERG liabilities, and had become our drug candidate **TAK-659**.

The synthesis of compound **3a** and **TAK-659** was performed according to the method depicted in **Scheme 3**.¹⁰ 2,6-dichloro-5-fluoronicotinic acid was lithiated via treatment with LDA in THF at -78°C. Quenching with DMF gave hemiacetal intermediate **5**, which underwent reductive amination through reaction with (2,4-dimethoxyphenyl)methanamine and NaBH₃CN. The resulting amino acid (not shown) was cyclized via amide coupling to form the lactam ring. Displacement of the chloro group of intermediate **6** with commercially available tert-butyl (1*S*, 2*R*)-2-amino-cyclohexyl-carbamate^{9b} was followed by Suzuki coupling with pyrazolo [1, 5-*a*] pyridin-3-ylboronic acid or (1-methyl-1*H*-pyrazol-4-yl) boronic acid, respectively. Final Boc deprotection of **7** afforded compounds **3a** and **TAK-659**.

Figure 3. Co-crystal structure of compound **TAK-659** in the SYK active site. C⁵-F displaced the HOH136 normally found bound between the core N and the backbone of Asp512.

Shown in **Figure 3** is a co-crystal structure of **TAK-659** in the SYK active site that was solved at 1.93 Å. **TAK-659** maintains all key interactions with the SYK active site. For example, the HBs between the lactam core and the hinge through Ala451 and Glu449, the methyl pyrazole ring occupying the lipophilic region with one of the nitrogens forming an HB with a water molecule, multiple interactions between the primary and secondary amines of the cyclohexyl ring with the polar region comprised of Arg498, Asn499, and Asp512, and the C⁵-F substituent disrupting the water-mediated network by displacing HOH136 (cyan).

280 kinases screened in house and at Invitrogen/Life Technologies showed that **TAK-659** was selective against most other kinases, but retained potency towards both SYK and FLT3 (**Tables 3-6**).¹⁰ In a cell proliferation assay, **TAK-659** showed inhibition towards a SYK-dependent cell line (OCI-LY10).¹¹ The

result demonstrated that the sensitivity to **TAK-659** was associated with mutations impacting SYK activity in B cell lymphomas, whereas **TAK-659** was not cytotoxic for adherent primary or solid tumor cell lines. In cell viability assays (**Figure 4** in supplemental data), **TAK-659** was shown to be sensitive toward FLT3-ITD dependent cell lines, MV4-11 and MOLM-13 while the WT FLT3 RS4-11 (ALL cell line) and RA1 (Burkitt's Lymphoma cell line) are not sensitive towards **TAK-659**. To

evaluate SYK inhibition *in vivo* in a pre-clinical immunology model, **TAK-659** was tested against an *in vivo* C57BL/6 mouse whole blood assay (**Figure 5** in supplemental data). The purpose of this assay was to evaluate CD86 (cluster of differentiation 86) expression after primary B-cell activation which was dependent on SYK activity. The result showed that **TAK-659** blocks anti-IgD (immune-globulin D antibody) stimulated CD86 expression in mouse peripheral B cells *in vivo*.

Table 1. Structure-activity relationship of **R** substituents on compound **1**. Cell EC₅₀ represents cellular p-BLNC inhibition in RA1/GFP-BLNC cells.

<div> </div>						
R	2a H	2b F	2c Cl	2d Me	2e CN	2f
SYK IC ₅₀ (nM)	4.7	1.1	0.8	3.1	0.5	0.9
Cell EC ₅₀ (nM)	5	9	NT	NT	< 3	4
Fold-Selectivity against individual SYK potency						
JAK3	70	170	53	18	3.3	10
ZAP70	23	29	19	9	3.5	0.5
VEGFR2	260	590	NT	NT	1,800	220
CYPs (>10 μM)	No	Yes	No	No	No	No
cLogP	4.1	4.3	4.7	4.6	3.9	4.1
LipE	4.2	4.7	4.4	3.9	5.4	5.0

Table 2. Lead optimization and discovery of **TAK-659**

	2b	3a	3b (TAK-659)
SYK IC₅₀ (nM)	1.1	2.3	3.2
Cell EC₅₀ (nM)	9	9	9.8
Fold-Selectivity against individual SYK potency			
JAK3	170	260	36
ZAP70	29	170	23
VEGFR2	590	2800	42
CYPs (>10 μM)	✓	✓	✓
cLogP	4.3	2.0	0.9
LipE	4.7	6.7	7.5
hERG (10μM)	47%	NT	<10%

Scheme 3. Reagents and conditions: (a) LDA, -78°C, DMF/THF, 1h, 80%; (b) (2,4-dimethoxyphenyl)methanamine, NaBH₃CN, AcOH, MeOH, rt, 4h, 74%; (c) EDC, HOBt, DMF, 2h, 90%; (d) tert-butyl (1S,2R)-2-amino-cyclohexylcarbamate, DIEA, ACN, 100°C, 2-4 days, 40%; (e) for **R**¹ = **3a**: pyrazolo[1,5-a]pyridin-3-ylboronic acid; for **R**¹ = **3b**: (1-methyl-1H-pyrazol-4-yl)boronic acid, Pd(PPh₃)₂Cl₂, Na₂CO₃, DME-H₂O, 100°C, o/n, 68%; (f) neat TFA, 60°C, 2h, 79%

Assessment of tumor growth inhibition in the OCI-LY10 xenograft and DLBCL PHTX-95L (primary human tumor graft from DLBCL patient) mouse models, **TAK-659** demonstrates potent tumor growth inhibition (TGI) after 20 days of treatment.

¹¹ In the FLT3-dependent MV4-11 xenograft model, **TAK-659** showed tumor regression at 60 mg/kg daily after 20 days of dosing.¹⁰

In conclusion, we have utilized high-throughput protein crystallography and SBDD to design a novel series of SYK inhibitors, which facilitated in the discovery and optimization of a potent and selective dihydropyrimidinone lead compound **1**. Displacement of water in the SYK active site enhanced potency and selectivity against JAK3, and replacement of the aniline and lowering of cLogP reduced hERG and reactive metabolite risk, which led to the discovery of **TAK-659**. **TAK-659** inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines, and shows notable TGI in SYK- and FLT3-dependent xenograft models. Clinical trials of **TAK-659** for the treatment of advanced solid tumors and lymphoma malignancies are ongoing.¹²⁻¹³

Acknowledgements:

We acknowledge the ADME group for generating the micro-somal and solubility data, and the cellular pharmacology group for generating cellular data. The X-ray crystallography data reported here are based on research conducted at the Advanced Light Source (ALS). ALS is supported by the Director, Office of Science, Office of Basic Energy Sciences, Materials Sciences Division, of the U.S. Department of Energy under Contract No. DE-AC03-76SF00098 at the Lawrence Berkeley National Laboratory. We thank the staff at ALS for their excellent support in the use of the synchrotron beamlines. The authors express their appreciation to Ron Chen, Gavin Hirst, Shota Kikuchi, Beverly Knight, Mitsunori Kouno, Matt Lardy, Sean Murphy, Lisa Rahbaek, Chris Smith, and Gyorgy Snell for their drug discovery advice.

References and notes:

- (a) Sada K.; Takano T.; Yamamura, H.; *J Biochem* **2001**, 130, 2, 177-186. (b) Wong, B.R.; Grossbard, E.B.; Payan, D.G.; Masuda, E.S.; *Expert Opin. Investig. Drug*, **2004**, 13, 7, 743-762. (c) Bogusz, A.M.; Baxter, R.H.; Currie, T.; Sinha, P.; Sohani, A.R.; Kutok, J.L.; Rodig, S.J.; *Clin Cancer Res.* **2012** Nov 15, 18, 22, 6122-35. (d) Chen, L.; Monti, S.; Juszczynski, P.; Daley, J.; Chen, W.; Witzig, T.E.; Habermann, T.M.; Kutok, J.L.; Shipp, M.A.; *Blood*, **2008** Feb 15, 111, 4, 2230-7. (e) Cheng, S.; Coffey, G.; Zhang, X.H.; Shakhovich, R.; Song, Z.; Lu, P.; Pandey, A.; Melnick, A.M.; Sinha, U.; Wang, Y.L.; *Blood*, **2011**, 118, 24, 6342-52. (f) Davis, R.E.; Ngo, V.N.; Lenz, G.; Tolar, P.; Young, R.M.; Romesser, P.B.; Kohlhammer, H.; Lamy, L.; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A.L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J.K.; Thomas, C.J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Johnson, N.A.; Rimsza, L.M.; Campo, E.; Jaffe, E.S.; Wilson, W.H.; Delabie, J.; Smeland, E.B.; Fisher, R.I.; Braziel, R.M.; Tubbs, R.R.; Cook, J.R.; Weisenburger, D.D.; Chan, W.C.; Pierce, S.K.; Staudt, L.M.; *Nature*, **2010**, 463, 7277, 88-92.
- (a) Davis, R.E., et al. *Nature* **2010**, 463, 7277, 88-92. (b) Efremov, D.G.; Laurenti, L.; *Expert Opin Investig Drugs*. **2011**, 20, 5, 623-36. (c) Knapper, S.; *Expert Opin Investig Drugs*, **2011**, 20, 10, 1377-95.
- (a) Zarinkar, P.P.; Gunawardane, R.N.; Cramer, M.D.; Gardner, M.F.; Brigham, D.; Belli, B.; Karaman, M.W.; Pratz, K.W.; Pallares, G.; Chao, Q.; Sprankle, K.G.; Patel, H.K.; Levis, M.; Armstrong, R.C.; James, J.; Bhagwat, S.S.; *Blood*, **2009** Oct 1, 114, 14, 2984-92. (b) Levis, M.; Small, D.; *Leukemia*, **2003**, 17, 1738-1752. (c) Kindler, T.; Lipka, D.B.; Fischer, T.; *Blood*, **2010** Dec 9; 116(24):5089-102.
- (a) Stirewalt, D.L.; Kopecky, K.J.; Meshinchi, S.; Engel, J.H.; Pogossova-Agadjanyan, E.L.; Linsley, J.; Slovak, M.L.; Willman, C.L.; Radich, J.P.; *Blood*, **2006** May 1, 107, 9, 3724-26. (b) Kottaridis, P.D.; Gale, R.E.; Frew, M.E.; Harrison, G.; Langabeer, S.E.; Belton, A.A.; Walker, H.; Wheatley, K.; Bowen, D.T.; Burnett, A.K.; Goldstone, A.H.; Linch, D.C.; *Blood*, **2001** September 15, 98, 6, 1725-59. (c) Puissant, A.; Fenouille, N.; Alexe, G.; Pikman, Y.; Bassil, C.F.; Mehta, S.; Du, J.; Kazi, J.U.; Luciano, F.; Rönstrand, L.; Kung, A.L.; Aster, J.C.; Galinsky, I.; Stone, R.M.; DeAngelo, D.J.; Hemann, M.T.; Stegmaier, K.; *Cancer Cell*, **2014** Feb 10, 25, 2, 226-242. (d) Pratz, K.; Levis, M.; *Leuk Lymphoma*, **2008** May, 49, 5, 852-863. (e) Hahn, C.K.; Berchuck, J.E.; Ross, K.N.; Kakoza, R.M.; Clauser, K.; Schinzel, A.C.; Ross, L.; Galinsky, I.; Davis, T.N.; Silver, S.J.; Root, D.E.; Stone, R.M.; DeAngelo, D.J.; Carroll, M.; Hahn, W.C.; Carr, S.A.; Golub, T.R.; Kung, A.L.; Stegmaier, K.; *Cancer Cell*, **2009** Oct 6, 16, 4, 281-294.
- Norman, P., *Expert Opin. Ther. Patents*, **2014**, 24, 5, 573-595.
- (a) Lucas, M.C.; Tan, S. L.; *Future Med. Chem.*, **2014**, 6, 16, 1811-1827. (b) AstraZeneca announces top-line results from Phase 3 OSKIRA Trials of FOSTAMATINIB and decision not to proceed with regulatory filings. Press Release, Tuesday, 4 June **2013**.
- (a) Weinblatt, M. E.; Kavanaugh, A.; Genovese, M.C.; Jones, D.A.; Musser, T.K.; Grossbard, E.B.; Magilav, D.B.; *J Rheumatol*, **2013**, 40, 4, 369-78. (b) Weinblatt, M.E.; Kavanaugh, A.; Burgos-Vargas, R.; Dikranian, A.H.; Medrano-Ramirez, G.; Morales-Torres, J.L.; Murphy, F.T.; Musser, T.K.; Straniero, N.; Vicente-Gonzales, A.V.; Grossbard, E.; *Arthritis Rheum*. **2008** Nov, 58, 11, 3309-18. (c) Moretto, A.F.; Dehnhardt, C.; Kaila, N.; Papaioannou, N.; Thorarensen, A.; *Recent Patents on Inflammation & Allergy Drug Discovery* **2012**, 6, 97-120. (d) Thoma, G.; Blanz, J.; Bühlmyer, P.; Drückes, P.; Kittelmann, M.; Smith, A.B.; Van Eis, M.; Vangrevelinghe, E.; Zerwes, H.; Che, J.; He, X.; Jin, Y.; Lee, C.C.; Michellys, P.; Uno, T.; Liu, H.; *Bioorg. Med. Chem. Lett.* **2014**, 24, 2278-2282.
- Protein Data Bank code: will be provided upon acceptance of the paper for publication.
- (a). Full experimental procedures for all syntheses are contained within the following patent: Arikawa, Y.; Jones, B.; Lam, B.; Nie, Z.; Smith, C.; Takahashi, M.; Dong, Q.; Feher, V.. Patent No.: **WO/2011/079051 A1**. **US20110152273 A1**, **2011**. (b). Optically pure tert-butyl (1S,2R)-2-amino-cyclohexyl-carbamate is commercially available from Aldrich and TCI-US, etc.
- Supplemental Data:
- Huck, J., et al. Antitumor activity of inhibiting SYK kinase with **TAK-659**, an investigational agent, in DLBCL models. Presented at **2014** American Society Of Clinical Oncology Annual Meeting; Chicago, Illinois. Abstract No: 8580
- (a). Petrich, A.M.; Gordon, L.I.; Infante, J.R., et al. Ongoing, first-in-human, phase I dose-escalation study of investigational SYK inhibitor **TAK-659** in patients with advanced solid tumors or lymphoma. Presented at: 13th International Conference on Malignant Lymphoma, **2015**; Lugano, Switzerland. Abstract 039. (b). Petrich, A.M.; Gordon, L.I.; Infante, J.R.; Madan, S.; Giles, F.J.; Nimeiri, H.S.; Kaplan, J.B.; Stumpo, K.; Zhang, B.; Faucette, S.; Shou, Y.; Shih, K.C.; 2693 Phase I Dose-Escalation Study of **TAK-659**, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. Presented at: 57th American Society of Hematology Annual Meeting, **2015**; Orlando, Florida. Lymphoma: Chemotherapy, excluding Pre-Clinical Models; Program: Oral and Poster Abstracts; Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models; Poster II. (c). Lam, B.; MEDI 30: Discovery of **TAK-659**, An Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK). Presented at 250th American Chemical Society National Meeting & Exposition, **2015**, Boston, USA
- Takeda global site disclosed **TAK-659** entering Phase Ib/II clinical trial for solid tumors and hematological malignancies. May, **2014**. Also obtained latest results from www.clinicaltrials.gov

Discovery of TAK-659, an Orally Available Investigational Inhibitor of Spleen Tyrosine Kinase (SYK)

Leave this area blank for abstract info.

Betty Lam*, Yasuyoshi Arikawa, Joshua Cramlett, Qing Dong, Ron de Jong, Victoria Feher Charles E. Grimshaw, Pamela J. Farrell, Isaac D. Hoffman, Andy Jennings, Benjamin Jones, Jennifer Matuszkiewicz, Joanne Miura, Hiroshi Miyake, Srinivasa Reddy Natala, Lihong Shi, Masashi Takahashi, Ewan Taylor, Corey Wyrick, Jason Yano, Jonathan Zalevsky, and Zhe Nie